SANDOZ NABUMETONE 500 MG
NABUMETONE : 500 MG · DIN 02242912 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED POST MARKET
What is SANDOZ NABUMETONE?
SANDOZ NABUMETONE 500 MG contains NABUMETONE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02242912, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Aug-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02242912 |
|---|---|
| Brand name | SANDOZ NABUMETONE |
| Generic / active ingredient | NABUMETONE : 500 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AX01 NABUMETONE |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Aug-2008 |
| Original market date | 2002-02-21 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M01AX01 NABUMETONE. 1 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NABUMETONE | 500 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02238639 |
| MYLAN-NABUMETONE | 500 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02244563 |
| NABUMETONE | 500 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02343282 |
| NABUMETONE | 500 MG | TABLET | APOTEX INC | APPROVED | DIN 02238369 |
| NABUMETONE-500 | 500 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02239113 |
| PMS-NABUMETONE | 500 MG | TABLET | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02238759 |
| PMS-NABUMETONE | 750 MG | TABLET | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02238760 |
| RELAFEN TABLETS 500MG | 500 MG | TABLET | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02083531 |
| RELAFEN TABLETS 750MG | 750 MG | TABLET | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02083558 |
| TEVA-NABUMETONE | 500 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02240867 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.